164 related articles for article (PubMed ID: 38048391)
41. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
[TBL] [Abstract][Full Text] [Related]
42. Carfilzomib 56 mg/m
Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
Leuk Lymphoma; 2022 Aug; 63(8):1887-1896. PubMed ID: 35289710
[TBL] [Abstract][Full Text] [Related]
43. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Dinner S; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG
Lancet Haematol; 2023 Oct; 10(10):e825-e837. PubMed ID: 37708911
[TBL] [Abstract][Full Text] [Related]
44. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
45. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ;
N Engl J Med; 2019 May; 380(22):2104-2115. PubMed ID: 31141632
[TBL] [Abstract][Full Text] [Related]
46. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
47. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Leukemia; 2022 Apr; 36(4):1066-1077. PubMed ID: 34974527
[TBL] [Abstract][Full Text] [Related]
48. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
49. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
50. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
[TBL] [Abstract][Full Text] [Related]
52. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Jakubowiak AJ; Kumar S; Medhekar R; Pei H; Lefebvre P; Kaila S; He J; Lafeuille MH; Cortoos A; Londhe A; Mavros P; Lin TS; Usmani SZ
Oncologist; 2022 Jul; 27(7):e589-e596. PubMed ID: 35462406
[TBL] [Abstract][Full Text] [Related]
53. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
[No Abstract] [Full Text] [Related]
55. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ
Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
Wong XY; Chng WJ; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
[TBL] [Abstract][Full Text] [Related]
57. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
58. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
59. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Dimopoulos M; Siegel D; White DJ; Boccia R; Iskander KS; Yang Z; Kimball AS; Mezzi K; Ludwig H; Niesvizky R
Blood; 2019 Jan; 133(2):147-155. PubMed ID: 30478094
[TBL] [Abstract][Full Text] [Related]
60. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
